{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:55:31Z","timestamp":1770987331509,"version":"3.50.1"},"reference-count":34,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2434,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1111\/j.1742-1241.2008.01900.x","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T12:44:19Z","timestamp":1222865059000},"page":"140-150","source":"Crossref","is-referenced-by-count":49,"title":["Olanzapine pamoate: a stick in time?"],"prefix":"10.1155","volume":"63","author":[{"given":"L.","family":"Citrome","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","reference":[{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.4088\/JCP.v67n1008","article-title":"Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review","volume":"67","author":"Valenstein","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.psc.2007.04.002","article-title":"Antipsychotic medication adherence in schizophrenia","volume":"30","author":"Byerly","year":"2007","journal-title":"Psychiatr Clin North Am"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4088\/JCP.v69n0107","article-title":"A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia","volume":"69","author":"Law","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB4","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1176\/appi.ps.55.8.886","article-title":"Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia","volume":"55","author":"Weiden","year":"2004","journal-title":"Psychiatr Serv"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB5","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-8-32","article-title":"Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia","volume":"8","author":"Morken","year":"2008","journal-title":"BMC Psychiatry"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2165\/00003495-200767110-00003","article-title":"Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives","volume":"67","author":"M\u00f6ller","year":"2007","journal-title":"Drugs"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB8","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"Suppl.","key":"10.1111\/j.1742-1241.2008.01900.x-BIB10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/0269881105059505","article-title":"Do guidelines for severe mental illness promote physical health and well-being?","volume":"6","author":"Citrome","year":"2005","journal-title":"J Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB11","volume-title":"Zyprexa Olanzapine Tablets, Zyprexa Zydis Olanzapine Orally Disintegrating Tablets, Zyprexa IntraMuscular Olanzapine for Injection","author":"Eli Lilly and Company"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB12","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4088\/JCP.v69n0512","article-title":"An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia","volume":"69","author":"Lauriello","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.npp.1301409","article-title":"D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia","volume":"33","author":"Mamo","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/02652040802033913","article-title":"Optimization of formulation variables for the development of long acting microsphere based depot injection of olanzapine","volume":"25","author":"Nahata","year":"2008","journal-title":"J Microencapsul"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB15","volume-title":"Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder (HGKB)","author":"Eli Lilly and Company"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB16","volume-title":"Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia (HGLQ)","author":"Eli Lilly and Company"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB17","volume-title":"Comparison of intramuscular olanzapine depot with placebo in the treatment of patients with schizophrenia (HGJZ)","author":"Eli Lilly and Company"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB18","volume-title":"Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and low-Dose Depot in Patients With Schizophrenia (HGKA)","author":"Eli Lilly and Company"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB19","first-page":"288S","article-title":"Pharmacokinetics (PK) of multiple doses of olanzapine long acting injection (OLAI), an intramuscular (IM) depot formulation of olanzapine (OLZ), in stabilized patients with schizophrenia [abstract]","volume":"63","author":"Kurtz","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB20","volume-title":"Long Term Open Label Study of Olanzapine Pamoate: Efficacy and Effect on Weight [Abstract]","author":"Horne"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2008.01900.x-BIB21","first-page":"151","article-title":"160-week interim results from an open-label extension trial of olanzapine long-acting injection [abstract]","volume":"11","author":"Detke","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2008.01900.x-BIB22","first-page":"151","article-title":"Olanzapine long-acting injection for the maintenance treatment of schizophrenia: a 24-week, randomized, double-blind trial [abstract]","volume":"11","author":"Detke","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2008.01900.x-BIB23","first-page":"152","article-title":"Olanzapine long-acting injection: An 8-week double-blind. randomized, placebo-controlled study in acutely-ill patients with schizophrenia [abstract]","volume":"11","author":"Detke","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2008.01900.x-BIB24","first-page":"152","article-title":"Comparison of metabolic parameters during treatment for schizophrenia with olanzapine intramuscular long-acting injection versus olanzapine oral formulation [abstract]","volume":"11","author":"Gulliver","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2008.01900.x-BIB25","first-page":"152","article-title":"Injection-related adverse events observed with olanzapine long-acting injection [abstract]","volume":"11","author":"Gulliver","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2008.01900.x-BIB26","first-page":"152","article-title":"Olanzapine long-acting injection: Pharmacokinetic and dose correspondence data relative to oral Olanzapine [abstract]","volume":"11","author":"Gulliver","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2008.01900.x-BIB27","first-page":"161","article-title":"Treatment completion rates of olanzapine and risperidone in long acting injectable formulations for the treatment of schizophrenia: a comparison of single arm open\u00b7label studies [abstract]","volume":"11","author":"Ascher-Svanum","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB28","volume-title":"Zyprexa Olanzapine Pamoate (OP) Depot, Psychopharmacological Drugs Advisory Committee Briefing Document","author":"Eli Lilly and Company"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB29","volume-title":"Clinical Review NDA 22-173, Olanzapine Pamoate Depot","author":"Zhang"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB30","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","article-title":"Compelling or irrelevant? Using number needed to treat can help decide","volume":"117","author":"Citrome","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB31","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1586\/14737175.8.7.1079","article-title":"Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks","volume":"8","author":"Citrome","year":"2008","journal-title":"Expert Rev Neurother"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00023210-200519020-00005","article-title":"Intramuscular olanzapine: a review of its use in the management of acute agitation","volume":"19","author":"Wagstaff","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB33","volume-title":"FDA Issues Not-Approvable Letter for Lilly\u2019s Zyprexa Long-Acting Injection (LAI) for Schizophrenia Treatment","author":"Eli Lilly and Company"},{"key":"10.1111\/j.1742-1241.2008.01900.x-BIB34","doi-asserted-by":"crossref","unstructured":"34 Kantrowitz J , Citrome L . Olanzapine: review of safety. Expert Opin Drug Saf 2008 (in press).","DOI":"10.1517\/14740330802423234"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2008.01900.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2008.01900.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:06:07Z","timestamp":1643349967000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2008.01900.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01900.x","relation":{},"ISSN":["1368-5031","1742-1241"],"issn-type":[{"value":"1368-5031","type":"print"},{"value":"1742-1241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}